A Clinical Study Evaluating the Efficacy of Systemic Chemotherapy and Immune Checkpoint Inhibitors Combined With Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer Patients With Peritoneal Metastasis

Korábbi kezelés

• Patients use immunosuppressant within 30 days prior to the initial use of tirelizumab, excluding nasal sprays and physiological doses of inhaled corticosteroids or systemic steroids from consideration.
• Patients have a documented history of ongoing autoimmune conditions or prior autoimmune diseases.

Más betegség

• Patients have other malignant tumors within the past 5 years.
• Patients are allergic to oxaliplatin, S-1, other related chemotherapy drugs or immune checkpoint inhibitors.
• Patients with epilepsy or other mental disorders.
• Patients who are unable to undergo surgery due to severe heart, lung and vascular diseases.

Egyéb

• Pregnant or lactating women.
• Patients with other distant metastasis

• 18-75 years
• Men, or non-pregnant and non-lactating women
• Pathological diagnosis as gastric malignant tumor
• diagnosis of peritoneal metastasis [peritoneal cancer index (PCI) ≤ 12 points] by laparoscopic exploration
• Normal major organ function:
• HB ≥ 90 g/L； ANC ≥ 1.5×109/L; plt ≥125×109/L; 2) TBIL<1.5ULN; ALT, AST <2.5ULN; Cr≤1.25ULN; ALB ≥ 30 g/L 6. Not receive radiation therapy, chemotherapy, targeted therapy, or immunotherapy.
• Eastern Cooperative Oncology Group Performance Status (ECOG): 0-1 8. Patients are volunteers, have signed informed consent, and agree to cooperate with investigators in data collection.